Tanvex BioPharma Inc (6541) - Total Liabilities

Latest as of March 2026: NT$2.27 Billion TWD ≈ $71.64 Million USD

Based on the latest financial reports, Tanvex BioPharma Inc (6541) has total liabilities worth NT$2.27 Billion TWD (≈ $71.64 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 6541 financial resilience to evaluate the company's liquid asset resilience ratio.

Tanvex BioPharma Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Tanvex BioPharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Tanvex BioPharma Inc assets under control.

Tanvex BioPharma Inc Competitors by Total Liabilities

The table below lists competitors of Tanvex BioPharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Zippy Technology Corp TW:2420	Taiwan	NT$1.69 Billion
Deutsche Real Estate AG F:DRE2	Germany	€98.68 Million
Tata Steel (Thailand) Public Company Limited BK:TSTH	Thailand	฿2.96 Billion
Saha-Union Public Company Limited BK:SUC	Thailand	฿2.41 Billion
Sygnia Ltd JSE:SYG	South Africa	ZAC174.28 Billion
Ledesma SAAI BA:LEDE	Argentina	AR$331.45 Billion
Orvana Minerals Corp. TO:ORV	Canada	CA$175.11 Million
Sam Yung Tradi KO:002810	Korea	₩105.96 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Tanvex BioPharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 6541 equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.42	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tanvex BioPharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual total liabilities of Tanvex BioPharma Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$2.27 Billion ≈ $71.43 Million	+23.09%
2024-12-31	NT$1.84 Billion ≈ $58.03 Million	-5.17%
2023-12-31	NT$1.94 Billion ≈ $61.19 Million	-4.24%
2022-12-31	NT$2.03 Billion ≈ $63.90 Million	+5.71%
2021-12-31	NT$1.92 Billion ≈ $60.45 Million	+9.52%
2020-12-31	NT$1.75 Billion ≈ $55.20 Million	+223.18%
2019-12-31	NT$542.12 Million ≈ $17.08 Million	+105.41%
2018-12-31	NT$263.92 Million ≈ $8.31 Million	+17.93%
2017-12-31	NT$223.78 Million ≈ $7.05 Million	-25.22%
2016-12-31	NT$299.25 Million ≈ $9.43 Million	+146.47%
2015-12-31	NT$121.41 Million ≈ $3.83 Million	+86.52%
2014-12-31	NT$65.09 Million ≈ $2.05 Million	-22.16%
2013-12-31	NT$83.63 Million ≈ $2.63 Million	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$257.13 Million

NT$8.16 Billion TWD

Market Cap Rank

#15635 Global

#698 in Taiwan

Share Price

NT$30.80

Change (1 day)

+0.82%

52-Week Range

NT$30.30 - NT$65.30

All Time High

NT$287.73